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Background: DAPK2 is a pro-apoptotic protein kinase that associates with TGFβ receptors. The homolog DAPK1
has been shown to mediate apoptosis in kidney injury. Expression databases indicate that DAPK2 is expressed in
the kidney, and in this work we investigate the localization of renal DAPK2 expression and its role in the kidney.
Results: Immunostaining demonstrates DAPK2 expression in interstitial cells of the renal cortex including PDGFRβ-
positive pericytes and the CD73-positive erythropoietin-expressing fibroblast population. Tubulointerstitial fibrosis in
experimental CKD arises directly from resident interstitial cells, and we therefore evaluated the expression of DAPK2
in the expanded interstitium of mice with kidney disease induced by chronic cisplatin administration. Expanded
renal interstitium in these animals was negative for DAPK2 expression, but healthy areas of the kidney in which the
tubular interstitium had not expanded expressed DAPK2 at levels similar to the uninjured control. Dapk2 null mice
were generated to evaluate if DAPK2 is required for formation of the kidney, or its maintenance in the adult.
Kidneys of Dapk2 null mice did not show overt malformations or age-related degeneration, but did show a slight
increase in the number of interstitial fibroblasts. Differences were seen between Dapk2 null mice and wild type
controls in the response to tubulointerstitial fibrosis caused by chronic cisplatin administration. Although mutant
and wild type mice displayed comparable levels of alpha smooth muscle actin, interstitial proliferation and SMAD2
signaling, Dapk2 null mice showed reduced interstitial collagen accumulation.
Conclusions: In the kidney, DAPK2 is strongly and specifically expressed in interstitial cells of the cortex, providing
a useful marker for this important cell population. Dapk2 null mice are phenotypically normal under steady state
conditions, but display some resistance to extracellular matrix deposition in experimental renal fibrosis indicating
that DAPK2 plays a profibrotic role in kidney injury.
Keywords: DAPK2, Kidney, Chronic kidney disease, Fibrosis, TGFβ, CisplatinBackground
Death Associated Protein Kinases (DAPKs) are of interest
in kidney disease because they have been associated with
both TGFβ signaling and apoptosis [1-6]. The founding
member of the family, DAPK1, is a mediator of renal tubu-
lar injury in ischemic and obstructive injury models [1-4].
DAPK1 is activated by signals including TGFβ, which plays
multiple roles in chronic kidney disease (CKD) [6]. In
mouse renal tubule epithelial cells, where it is specifically
expressed, DAPK1 mediates apoptosis through activation
of p53 [1-5].
The role of the related protein DAPK2 in kidney injury
has yet to be determined. DAPK2 is the smallest of the* Correspondence: Wojchd@mmc.org; Oxburl@mmc.org
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kinase domain with 80% identity to that of DAPK1 and
also shares a calmodulin-binding domain with DAPK1.
Unlike DAPK1, DAPK2 possesses no cytoskeletal binding
domains or other characteristic protein binding domains,
and instead contains a homodimerization domain that fa-
cilitates the activation of the protein kinase domain [7,8].
Dapk2 is involved in autophagy and membrane blebbing
both with and without complete apoptosis [7].
In vitro, DAPK2 responds to cellular stress signaling in-
duced by TNFα and Fas by inducing apoptosis [9]. Dapk2
is downregulated by Wnt/β-catenin and this downregula-
tion is associated with resistance to apoptosis induced by
loss of cell adhesion (anoikis) [10]. Dapk2 is transcription-
ally regulated by E2F1, KLF6, and SP1, a group of factors
that coordinately regulate the cell cycle, apoptosis andd. This is an Open Access article distributed under the terms of the Creative
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ing partner of TGFβ receptor I in a protein binding assay,
although this association has yet to be functionally vali-
dated [12].
Public databases report expression of Dapk2 transcript
in several organs including kidney, lung, skeletal muscle,
colon, breast, and spleen. DAPK2 is also expressed in
leukocytes and erythroblasts where it is involved in their
differentiation [13,14]. Considering the intriguing finding
that Dapk2 is expressed in the adult kidney, and is asso-
ciated with TGFβ signaling, we set out to clarify the
localization of DAPK2 protein expression in the kidney
and to ascertain if Dapk2 is required for renal develop-
ment or maintenance. We find that DAPK2 protein is
expressed in interstitial cells of the adult kidney includ-
ing PDGFRβ-positive pericytes and CD73-positive fib-
roblasts. Functional analysis suggests that while Dapk2
does not regulate interstitial proliferation or smooth
muscle actin expression in CKD, it does promote extra-
cellular matrix deposition.
Results and discussion
Dapk2 loss of function mouse strain
To determine the localization and role of Dapk2 in vivo
we developed a Dapk2 null mouse strain. In this strain, the
initiation codon and first portion of the kinase domain are
deleted by replacement of exon 2 with a PGK:Neo cassette
(Figure 1A). Western blot analysis using a polyclonal anti-
body raised to the C-terminus of the DAPK2 protein con-
firms loss of DAPK2 expression in the kidney (Figure 1B).
Dapk2 null mice were bred as a homozygous strain and
displayed no overt abnormalities. Histological analysis of
Masson’s Trichrome staining (Figure 1C-D), alpha smooth
muscle actin (αSMA) staining (Figure 1E,F) and bromo-
deoxyuridine (BrdU) incorporation (not shown) showed
no differences in kidney morphology, proliferation or col-
lagen deposition in Dapk2 null mice compared to wild
type controls, but a reduction in the area of αSMA stain-
ing in Dapk2 null mice (Figure 1G). This reduction is seen
largely in the renal interstitium, suggesting a difference in
fibroblast or vascular mural cell abundance or expression
of αSMA. In counts of CD73 positive fibroblasts cells in
two histological sections of three individuals from each
genotype we found a total of 114 positive cells in wild
types and 159 positive cells in Dapk2 null supporting a
skewing of interstitial cell populations in the null.
DAPK2 is expressed in a subset of renal interstitial cells
A survey of the Gene Expression Omnibus (GEO) database
reveals expression of Dapk2 transcript in numerous tissues
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=geo&term=-
dapk2). The publicly available Genito-Urinary Development
Molecular Anatomy Project (GUDMAP.org) repository
identifies several subsets of embryonic and adult kidneycell types in which Dapk2 is expressed [15]. These include
small blood vessels and podocytes in the embryo, and the
renal capsule, mesangium, mesangial capillaries, and me-
dullary vasculature in the adult.
To specifically localize DAPK2 expression within the
kidney, we performed immunofluorescent staining of kid-
ney sections using a N-terminal specific monoclonal anti-
body. Specificity of the anti-DAPK2 antibody was validated
using tissue sections from the Dapk2 null mouse. Very
weak background staining can be detected in some glom-
eruli in the null control tissue precluding definitive con-
firmation of glomerular Dapk2 expression (Figure 2A-C,
insets). Strong and specific signal is seen in the interstitium
of wild type tissue under the same conditions, indicating
that DAPK2 is expressed in cells located within the peri-
tubular space.
DAPK2 localizes with a high degree of specificity to a
subset of cortical peritubular interstitial cells that are most
abundant at the outer edge of the renal cortex between
the capsule and the most cortical glomeruli and extends in
a diminishing gradient to the cortical-medullary boundary
(Figure 2A-C). This observation was supported by western
blot of tissue isolated from distinct regions of the kidney
(Figure 2D). In contrast to the interstitial expression seen
in mouse, human kidney tissue displays DAPK2 expres-
sion in epithelial cells of Lotus Lectin expressing proximal
tubules (Figure 2E). This is an interesting difference be-
cause it implies that DAPK1 and DAPK2 are co-expressed
in the proximal tubule of the human kidney [5]. Analysis
of embryonic and postnatal stages shows no DAPK2 ex-
pression at E15.5, P0, or P3, but sporadic and weak ex-
pression in interstitial cells at P14 (Figure 2F-I).
To further characterize the DAPK2 expressing cell popu-
lation in mouse, co-localization studies using markers for
prevalent cell types within the renal interstitium were
performed. Staining with proximal tubule specific Lotus
Lectin (Figure 2A-C) and distal tubule specific E-cadherin
[16-18] (Figure 3A) confirmed that DAPK2 expressing
cells reside outside the nephron. Co-staining with the
antibody F4/80-BM8 demonstrated that DAPK2 expres-
sion does not co-localize with the network of dendritic
cells or with macrophages within the kidney [19,20]
(Figure 3B). MECA32 (PAL-E/anti-PV-1) a membrane
associated vascular-endothelial marker [21-24] did not
overlap with cytoplasmic DAPK2 (Figure 3C and insets),
indicating that DAPK2 is not expressed in vascular
endothelial cells. Because of the proximity of DAPK2 to
endothelial cells, we next looked to see if DAPK2 was
expressed in pericytes using an antibody specific for
PDGFRβ. DAPK2 and PDGFRβ antibodies were both of
the same species and not useful for co-staining. We
therefore stained adjacent sections for DAPK2 and
PDGFRβ respectively and assessed the correlation of ex-
pression between the two proteins. Interestingly, we
Figure 1 Dapk2 null mice possess fewer αSMA expressing interstitial cells. (A) Exon 2, containing the translation start site, was replaced
by a PGK:NEO cassette with internal LoxP and FRT sites. (B) Western blotting using a polyclonal c-terminal specific antibody demonstrates that
the null mouse does not express DAPK2 at the protein level in kidney. Representative Masson’s Trichrome staining from six (C) wild type and
(D) six Dapk2 null kidney sections show no gross histological differences between genotypes. (E-F) Representative αSMA staining (black arrows)
showing fewer positive interstitial cells in mutant mice. (G) Graph depicting the relative levels of staining between mice of both genotypes
normalized to wild type values. Quantitative analysis is based on 15 fields in untreated mice. Scale bars = 50 μM. Dashed circles mark glomeruli.
Abbreviations: B, BamHI; H, HindIII; K, KpnI; R, EcoRI; LA, long arm of targeting construct; SA, short arm of targeting construct.
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(Figure 3E) with the much more numerous PDGFRβ ex-
pressing pericytes (Figure 3E’). The correlated domains
of expression demonstrate that DAPK2 is expressed by
renal pericytes.
To test the possibility that DAPK2 is expressed in
renal interstitial fibroblasts, we compared DAPK2 stain-
ing with CD73, which is expressed in interstitial fibro-
blasts throughout the cortex [25]. DAPK2 and CD73antibodies are also not compatible for co-staining, ne-
cessitating immunostaining of adjacent sections. Inter-
estingly, adjacent section staining for DAPK2 (Figure 3F)
and CD73 (Figure 3F’) revealed a strong correlation of
localization. CD73 expression within the renal inters-
titium correlated with DAPK2 expression in adjacent
sections, while many of the more numerous DAPK2
positive cells did not express CD73. DAPK2 may thus be
a broad marker of cortical renal interstitial fibroblasts
Figure 2 Cortical peritubular expression of DAPK2 in kidney. (A-C) Representative immunofluorescent images of DAPK2 staining (white
arrows) of six wild type mice. Kidney sections from six Dapk2 null mice were used as specificity controls for the antiserum (insets A-C). Dashed
circles indicate nonspecific staining in glomeruli. DAPK2 was localized to a population of interstitial cells that extend from (A) the renal cortex to
(B) the cortical-medullary boundary. (C) No expression of DAPK2 was found in the inner medulla. (D) Western Blot analysis of tissue samples from
regions of the kidney confirms expression of DAPK2 specifically in the cortex. (E) Immunofluorescence of DAPK2 using the same antibody in
human kidney shows specific staining in proximal tubules (white arrows). Immunofluroescence images of DAPK2 staining at embryonic and
postnatal stages (F) E15.5, (G) P0, (H) P3, and (I) P14. Expression is seen only at P14 (arrow). Scale bars = 50 μm.
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population. CD73 is a well established marker of the
erythropoietin expressing cells of the deep cortex of the
kidney [26]. The association of DAPK2 and CD73 there-
fore implies that DAPK2 is expressed in the erythropoi-
etin expressing fibroblast population.
Identification of the DAPK2 expressing cells as peri-
tubular fibroblasts was attempted using anti-fibroblast
specific protein 1 (FSP1). Co-staining with anti-DAPK2and anti-FSP1 showed no co-localization (data not shown).
However, FSP1 expression was found in the medulla, in
cells that morphologically resembled polymorphonuclear
cells as described by others [27,28].
DAPK2 expression is lost in the expanded tubular
interstitium of the fibrotic kidney
The majority of myofibroblast accumulation in experimen-
tal CKD is derived from resident cells of the peritubular
Figure 3 DAPK2 is expressed in cortical peritubular fibroblasts. Co-immunofluorescent staining with molecular markers excluded DAPK2
expression (white arrows) from three major cell types. Proximal and distal tubules were excluded via (Figure 2A-C) lotus lectin and (A) E-cadherin
staining (open arrow), (B) dendritic cells and macrophage positive for F4/80-BM8 (open arrow) did not co-localize with DAPK2, and (C) endothelial cells
marked with membrane localized Meca32 (open arrow) were close to but did not co-localize with DAPK2 (inset green and red channels of dashed box
area). (D) Smooth muscle cells marked by αSMA did not co-localize with DAPK2 staining (inset: cyan and red channels of dashed box area). Adjacent
staining with the pericyte and fibroblast specific marker (E,E’) PDGFRβ and (F,F’) CD73 respectively, correlated positively with DAPK2 antibody labeling.
Immunofluorescent images are representative of three wild type mice analyzed for each antibody. White arrows, white arrowheads, and black
arrowheads correspond with equivalent positions between panels and adjacent ‘prime’ panels. Scale bars = 50 μm.
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with expanded fibrotic interstitium [29,30]. To answer this
question we evaluated DAPK2 expression in kidneys sub-
jected to seven weeks of chronic cisplatin administration.
Chronic cisplatin treatment induces increased collagen de-
position across the kidney with little morphologically de-
tectable damage to the nephron epithelium [31] and results
in a strong fibrotic response with significant expansion of
resident interstitial cells that express αSMA [29,30]. Wild
type mice were treated with 3 mg/kg cisplatin seven times
at seven day intervals and harvested 52 days after the first
injection. Compared to untreated controls (Figure 4A-C),
DAPK2 expression in cisplatin treated kidneys was
not seen in regions in which the interstitium was ex-
panded, but was instead seen in morphologically normalinterstitium surrounding nephrons containing Lotus
Lectin positive brush borders (Figure 4D-F). Based on
these findings we hypothesized that DAPK2 expression
may be downregulated in the process of interstitial cell
proliferation. To support this hypothesis, we cultured pri-
mary renal fibroblasts derived from the outer renal cor-
tex (Figure 4G). These primary cells were positive for
Vimentin and expressed DAPK2 (Figure 4H-J). DAPK2
was not differentially expressed in closely associated high-
density cells or in sparse, low-density cells (Figure 4I,J).
We next monitored DAPK2 expression in confluent cells
by immunoblot. Following outgrowth of isolated cells,
DAPK2 could readily be detected by immunoblotting.
However, after a single passage DAPK2 could no longer
be detected, suggesting that DAPK2 expression may either
Figure 4 DAPK2 is not expressed in fibrotic cells. Representative immunofluorescence of kidney tissue from ten fields analyzed in two wild
type (A-C) uninjured and (D-F) chronic cisplatin injured mice shows no DAPK2 staining in the expanded αSMA positive interstitium of injured
mice, white arrows indicate DAPK2 positive cells, open arrows indicate αSMA positive cells. (G) Schematic of primary fibroblast isolation.
(H) Representative immunofluorescent staining of ten fields of cultured primary fibroblasts for the fibroblast marker vimentin in primary cells at
passage 0. Representative immunofluorescent staining of ten fields of cultured primary fibroblasts for DAPK2 in (I) high and (J) low density
primary cells at passage 0. (K) Immunoblot of DAPK2 expression in isolated real fibroblasts demonstrating loss expression of DAPK2 after
expansion and passage, arrow indicates DAPK2 band, higher band shows β − Tubulin loading control. Scale bars = 50 μm.
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pressing cells suffer a proliferative disadvantage and are
out competed in culture (Figure 4K).
Loss of Dapk2 influences the fibrotic response to chronic
cisplatin treatment
To evaluate the role of Dapk2 in CKD we next treated 12
wild type and 12 Dapk2 null mice with chronic cisplatin
injections as described above. Compared to untreated con-
trols, both genotypes showed increases in collagen depos-
ition (blue stain in Masson’s trichrome), αSMA expression,
and proliferation (BrdU incorporation). A significant dif-
ference could be seen in trichrome staining (Figure 5A,B),
with Dapk2 null kidneys displaying approximately 20% less
collagen deposition (Figure 5I). However, levels of αSMA
(Figure 5C-D) and proliferation (Figure 5E,F) were com-
parable between wild type and null injured mice. Because
DAPKs act as modulators of TGFβ signaling in other sys-
tems, we also evaluated activation of the TGFβ pathway by
immunostaining for phosphorylated SMAD2. However, nodifference could be detected between wild type and null
injured mice (Figure 5G,H). Collagen deposition is a key
feature of tubulointerstitial fibrosis, and the finding that
Dapk2 null kidneys are moderately protected suggests that
DAPK2 may play a role directly in the collagen deposition
pathway. However, the role of DAPK2 in this process ap-
pears to be downstream of TGFβ mediated SMAD signal-
ing because the level of interstitial SMAD2 signaling is not
significantly different between the two genotypes.
To further assess the observed difference in collagen
staining seen via Masson’s Trichrome we stained chronic
cisplatin injured kidneys for Collagens IV, I, and III.
(Figure 6A-F). In our analysis of at least nine mice and 54
40× images for each genotype we found no significant differ-
ence in Collagen IV or Collagen III staining area, but a trend
toward reduction in Collagen I staining area (Figure 6G).
Conclusion
In this study we have shown that DAPK2 is expressed in
peritubular interstitial cells of the renal cortex including
Figure 5 Dapk2 null mice show resistance to fibrosis. In a chronic cisplatin induced model of CKD, 12 wild type and 10 mutant animals were
analyzed for markers of fibrosis. Representative images show (A,B) reduced collagen deposition in the Dapk2 null as demonstrated by
representative Masson’s trichrome staining (blue color indicated by arrows), and similar levels of (C,D) αSMA and (E,F) BrdU staining after
treatment (arrows indicate positive cells, ‘a’ indicates arterial smooth muscle). (G,H) pSMAD2 staining after treatment showing equivalent
numbers of positive interstitial nuclei, white arrows indicate positive pSMAD2 interstitial nuclei, open arrows indicate pSMAD2 negative nuclei.
(I) Graph depicting the relative levels of staining between cisplatin treated of both genotypes normalized to untreated wild type values.
Quantitative analysis is based on 100 fields in cisplatin treated mice. Dashed circles = glomeruli, scale bars = 50 μM.
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renal fibroblast populations in the mouse. In contrast to
the mouse, DAPK2 is expressed in epithelial cells of the
nephron in the human kidney, where published studies
indicate DAPK1 is also expressed [5]. This has important
implications for the translation of kinase specific inhib-
ition or activation between mice and humans. AdultDapk2 null mice have morphologically normal kidneys,
but when challenged with chronic cisplatin administra-
tion they display a decreased propensity for extracellular
matrix deposition in the interstitial space. While there
was no statistical significance in collagen staining in in-
jured mice, Collagen I trended toward a decreased stain-
ing area in the Dapk2 null. This suggests that some
Figure 6 Immunostaining for specific collagens. Immunofluorescent staining of wild type and Dapk2 null mice for (A,B) Collagen IV,
(C,D) Collagen I, and (E,F) Collagen III showing a trend toward decreased deposition of Collagen I only. Arrow show examples of positive
staining for each collagen. (G) Graph showing the relative collagen staining area from at least 54, 40× fields per genotype. Scale bars = 50 μM
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responsible for the difference in gross collagen area ob-
served between wild type and mutants. Based on these
observations we conclude that DAPK2 promotes tubu-
lointerstitial fibrosis in the mouse.
Methods
Animals
Animal care in accordance with the National Research
Council Guide for the Care and Use of Laboratory Ani-
mals was approved by the Maine Medical Center IACUC.
Except where indicated all animals used were 6–8 weeks
of age. Dapk2 null mice were generated as in [32]. Dapk2
genomic clones were isolated from a 129svJ λ phage library
by hybridization to a Dapk2 cDNA. A targeting vector
containing a PGK:Neo selection cassette was transfected
into ES cells and cells were subjected to G418 drug selec-
tion and cloned. Homologous recombination was detected
by southern blotting and targeted cells were injected into129SV/J blastocysts. Progeny of chimeras were bred
with 129SV/J mice for five generations before analysis.
Dapk2+/−mice were intercrossed to yield Dapk2 null mice.
The Dapk2 null strain was maintained on a 129SV/J back-
ground and wild type controls were 129SV/J. 12 wild type
and 10 mutant mice were intraperitoneally injected with
3 mg/kg cisplatin seven times at 7 day intervals. Kidneys
were harvested at 52 days after the first injection. Treated
animals were analyzed relative to four untreated mice of
both genotypes.
Primary cell isolation
Dissected kidneys were cut sagittally and the cortical
region of the kidney was separated. Cortical sections
were placed onto tissue culture plates coated with 1%
gelatin. Minced kidney bits were spread across the gel-
atin plate by scratching with a razor blade. After air-drying
for 5 min at 37°C fibroblast enrichment medium (20% Bo-
vine Growth Serum, DMEM) with Penicillin-Streptomycin,
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to grow. Cells were passaged at confluency to 1% gelatin
coated plates.
Immunostaining
Tissue was fixed in 4% paraformaldehyde for 1 hour per
millimeter thickness at room temperature before paraffin
sectioning. Immunohistochemical samples were treated
for 10 minutes in 1% H2O2. All antibody assays except
before anti-CD73 were treated by antigen unmasking
using citrate buffer (Dako Cytomation, 1:10 dilution) and
boiling for 10 minutes. Primary antibody concentrations:
1:50 α-smooth muscle actin (Invitrogen); 1:25 CD73 (BD
Biosciences); 1:50 Collagen I (Rockland); 1:50 Collagen III
(Rockland); 1:50 Collagen IV (Rockland); 1:50 DAPK2
(Epitomics); 1:100 F4/80–BM8 (Santa Cruz Biotech);
1:200 Lotus Lectin (Vector Labs); 1:50 MECA32 (De-
velopmental Studies Hybridoma Bank; 1:50 PDGFRβ
(Epitomics). Secondary antibodies: 1:200 goat anti-rabbit
Alexa568 (Invitrogen); 1:200 mouse anti-rat biotin (Jackson
Immunoresearch); 1:200 Avidin-488 (Invitrogen). TUNEL
staining was performed using the Apoptag® Peroxidase
in situ kit (Millipore) according to the manufacturer’s
protocol. Biotinylated secondary antibody incubation was
done in PBS at Room Temperature for 45 minutes, fol-
lowed by R.T.U ABC Elite Reagent incubation at Room
Temperature for 30 minutes. Sections were then visualized
using Sigma Fast 3,3’-diaminobenzidine (Sigma-Aldrich).
After color development sections were counterstained
with Meyers hematoxylin, coverslipped and mounted
with Cytoseal 60 (Richard-Allan Scientific).
Quantitative analysis of histochemistry
Images (.tif ) were cropped and analyzed by Color Thresh-
old for area or nuclei count using ImageJ. Values were nor-
malized to the total image area minus the area of white
space. 15 histological sections from a total of four mice
were analyzed for each genotype of untreated control mice.
100 histological sections from a total of seven mice were
analyzed for each genotype in Cisplatin treated mice. Tri-
chrome analysis was performed at 40×, while αSMA and
BrdU analysis was carried out at 20×.
Immunoblot
Analysis was performed on 10% acrylamide gels, trans-
ferred onto nitrocellulose membranes, blocked in 5% BSA
for 30 min and incubated in primary antibody over night
at 4°C. Primary antibody concentrations: 1:5,000 DAPK2
(Chemicon) and 1:5,000 β-tubulin (Santa Cruz Biotech).
Secondary antibody concentrations: 1:40,000 anti-rabbit-
HRP (Jackson Immunological). Blots were developed using
HyGLO chemiluminescent HRP antibody detection regent
(Denville Scientific).Availability of supporting data
No supporting data.
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